TY - JOUR
T1 - An international, multicenter, retrospective study on the positive impact of cutaneous involvement on the clinical outcome of adult T-cell leukemia/lymphoma
AU - Grupo de Estudio Latinoamericano de Linfoproliferativos (GELL)
AU - Malpica, Luis
AU - Castro, Denisse
AU - Enriquez, Daniel J.
AU - Oviedo-Pecho, Roberto
AU - Peña, Camila
AU - Idrobo, Henry
AU - Fiad, Lorena
AU - Prates, Maria
AU - Valcarcel, Bryan
AU - Paredes, Antonio
AU - Sánchez, Gadwyn
AU - Moisés, Celia
AU - Castillo, Jorge J.
AU - Villela, Luis
AU - Ramos, Juan C.
AU - Biglione, Mirna
AU - Beltran, Brady E.
N1 - Publisher Copyright:
© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Adult T-cell leukemia/lymphoma (ATLL) is a largely incurable disease. Cutaneous involvement is common and could be first symptom of the disease. We analyzed 169 patients with ATLL of whom 63 had cutaneous involvement. Cutaneous involvement was found in 48, 27, 17, and 60% of acute, lymphomatous, chronic and smoldering ATLL cases, respectively. Eight cases had primary cutaneous tumoral variant. Erythroderma (24%) and plaques (22%) were the most frequent skin lesions. The presence of cutaneous involvement was associated with better overall survival compared to non-cutaneous involvement (aHR 0.55 [95% CI: 0.37–0.82], p < 0.01; 1-year OS 53 vs. 27%, respectively, p = 0.012). Combination zidovudine and interferon-alpha (AZT-IFN) yielded high response rates (overall response, OR = 100%, n = 8; complete response 62.5%) compared to chemotherapy (OR = 33.3%, n = 12/36). In conclusion, cutaneous involvement was associated with better survival in Latin American patients with ATLL. AZT-IFN demonstrated encouraging responses in ATLL patients with cutaneous involvement.
AB - Adult T-cell leukemia/lymphoma (ATLL) is a largely incurable disease. Cutaneous involvement is common and could be first symptom of the disease. We analyzed 169 patients with ATLL of whom 63 had cutaneous involvement. Cutaneous involvement was found in 48, 27, 17, and 60% of acute, lymphomatous, chronic and smoldering ATLL cases, respectively. Eight cases had primary cutaneous tumoral variant. Erythroderma (24%) and plaques (22%) were the most frequent skin lesions. The presence of cutaneous involvement was associated with better overall survival compared to non-cutaneous involvement (aHR 0.55 [95% CI: 0.37–0.82], p < 0.01; 1-year OS 53 vs. 27%, respectively, p = 0.012). Combination zidovudine and interferon-alpha (AZT-IFN) yielded high response rates (overall response, OR = 100%, n = 8; complete response 62.5%) compared to chemotherapy (OR = 33.3%, n = 12/36). In conclusion, cutaneous involvement was associated with better survival in Latin American patients with ATLL. AZT-IFN demonstrated encouraging responses in ATLL patients with cutaneous involvement.
KW - ATLL
KW - Adult-T cell leukemia/lymphoma
KW - HTLV-1
KW - Latin America
KW - interferon alpha
KW - skin lymphoma
UR - http://www.scopus.com/inward/record.url?scp=85116459313&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116459313&partnerID=8YFLogxK
U2 - 10.1080/10428194.2021.1984455
DO - 10.1080/10428194.2021.1984455
M3 - Article
C2 - 34585997
AN - SCOPUS:85116459313
SN - 1042-8194
VL - 63
SP - 315
EP - 325
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 2
ER -